Stockreport

Bayer Reports Results for the Investigational Targeted Radionuclide Therapy ²²5Ac-PSMA-Trillium in Advanced Metastatic Prostate Cancer

BAYER AG S/ADR  (BAYRY) 
NASDAQ:AMEX Investor Relations: investor.bayer.com
PDF  225Ac-PSMA-Trillium (BAY 3563254) is an investigational targeted alpha therapy (TAT) being developed for patients with advanced metastatic castration-resistant prostate [Read more]